GyreOx’s proprietary discovery platform creates unique Gyrocycle™ highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules.
GyreOx’s proprietary discovery platform creates unique Gyrocycle™ highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website https://www.gyreox.com/
